Free Trial
LON:HLN

Haleon Final Earnings Report

Haleon logo
GBX 336.80 +2.80 (+0.84%)
As of 06/12/2026 12:22 PM Eastern

Haleon EPS Results

Actual EPS
GBX 18.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Haleon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Haleon Announcement Details

Quarter
Final
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Haleon Earnings Headlines

SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.tc pixel
Haleon PLC (HLN) Gets a Buy from Goldman Sachs
9 Best IPO Stocks to Buy in 2026
See More Haleon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Haleon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Haleon and other key companies, straight to your email.

About Haleon

Haleon (LON:HLN) (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

View Haleon Profile